Nivatrotamab

恩依妥单抗

Report date: 2026/03/19 16:46:37

Base Information

Drug NameNivatrotamab
Drug Alias NameHu3F8 bispecific antibody (Y-mAbs Therapeutics)huGD2-BsAbHu3F8-BsAb (GD2xCD3)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionDisialoganglioside GD2 inhibitorsT-cell surface glycoprotein CD3 epsilon chain modulators
TargetsDisialoganglioside GD2T-cell surface glycoprotein CD3 epsilon chain
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaNeuroblastoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesY-Mabs Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursSmall Cell Lung CarcinomaNeuroblastoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A